Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial | Reuters

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.